Infanrix™-IPV/Hib

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Acellular PertussisDiphtheriaHaemophilus Influenzae Type bInfections, StreptococcalInfluenzaPoliomyelitisStreptococcus Pneumoniae VaccinesTetanus

Phase 2

Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children

TerminatedNCT01003418

GlaxoSmithKlineInfluenza

Start: 2009-11-17End: 2010-11-25Updated: 2019-02-15

Phase 3

Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.

CompletedNCT00609492

GlaxoSmithKlineInfections, Streptococcal, Streptococcus Pneumoniae Vaccines

Start: 2008-01-03End: 2009-03-30Updated: 2020-01-03

Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)

CompletedNCT00964028

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Haemophilus Influenzae Type b +2

Start: 2009-12-01End: 2010-04-12Updated: 2018-06-06

Related Papers

Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and<i>Haemophilus influenzae</i>type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants

Human Vaccines & Immunotherapeutics2016-10-2116 citations